Portal de investigación
Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
Fecha de publicación:
Autores organización
Autores
- Mayorga D.
- Ruiz-Patiño A.
- Rodríguez J.
- Archila P.
- Avila J.
- Bravo M.
- Ricaurte L.
- Sotelo C.
- Arrieta O.
- Zatarain-Barrón Z.L.
- Carranza H.
- Otero J.
- Vargas C.
- Barrón F.
- Corrales L.
- Martín C.
- Recondo G.
- Pino L.E.
- Bermudez M.A.
- Gamez T.
- Ordoñez-Reyes C.
- García-Robledo J.E.
- de Lima V.C.
- Freitas H.
- Santoyo N.
- Malapelle U.
- Russo A.
- Rolfo C.
- Rosell R.
Grupos de investigación
Resumen
Background: Human papilloma virus (HPV) has been associated with the development and modulation of response in a series of neoplasms. In the case of lung adenocarcinoma, its role in etiology and pathogenesis is still controversial. Considering that this infection brings foreign epitopes, it could be of prognostic significance in patients with lung adenocarcinoma treated with immunotherapy. Methods: In a retrospective cohort study we evaluated the presence of HPV genomic material in lung adenocarcinoma primary lesions with the INNO-LiPA platform. Viral replication was also evaluated by detecting the presence of oncoprotein E6/E7 messenger RNA (mRNA) by quantitative RT-PCR. To confirm possible hypotheses regarding viral oncogenesis, vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (HIF1) were evaluated with stromal fibrosis and immunoscore. Results: A total of 133 patients were included in the analysis, of whom 34 tested positive for HPV, reaching an estimated prevalence of 25.6% [95% confidence interval (CI) 18.2% to 32.9%]. E6/7 mRNA was identified in 28 out of the 34 previously positive cases (82.3%). In immune checkpoint inhibitor (ICI)-treated patients, the median overall survival reached 22.3 months [95% CI 19.4 months- not reached (NR)] for HPV-negative and was not reached in HPV-positive (HPV+) ones (95% CI 27.7-NR; P = 0.008). With regard to progression-free survival, HPV- patients reached a median of 9.2 months (95% CI 7.9-11.2 months) compared to 14.3 months (95% CI 13.8-16.4 months) when HPV was positive (P = 0.001). The overall response rate for HPV+ patients yielded 82.4% compared to 47.1% in negative ones. No differences regarding programmed death-ligand 1, VEGF, HIF1, stromal fibrosis, or immunoscore were identified. Conclusions: In patients with HPV+ lung adenocarcinoma, a significant benefit in overall response and survival outcomes is observed. © 2022 The Authors
Datos de la publicación
- ISSN/ISSNe:
- 2059-7029, 2059-7029
- Tipo:
- Article
- Páginas:
- -
- Enlace a otro recurso:
- www.scopus.com
Esmo Open Elsevier B.V.
Citas Recibidas en Web of Science: 2
Citas Recibidas en Scopus: 7
Documentos
- No hay documentos
Filiaciones
Keywords
- Adenocarcinoma of Lung; Fibrosis; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Papillomavirus Infections; Retrospective Studies; RNA, Messenger; Vascular Endothelial Growth Factor A; afatinib; bevacizumab; cigarette smoke; epidermal growth factor receptor; erlotinib; gefitinib; hypoxia inducible factor 1; immune checkpoint inhibitor; messenger RNA; pembrolizumab; protein E6; protein E7; vasculotropin; messenger RNA; vasculotropin A; adenosquamous carcinoma; adult; Article; cancer immunotherapy; carcinogenesis; clinical outcome; cohort analysis; female; follow up; human; Karnofsky Performance Status; lung adenocarcinoma; lymphocytic infiltration; major clinical study; male; molecular fingerprinting; monotherapy; mRNA expression level; overall response rate; overall survival; papillomavirus infection; progression free survival; real time polymerase chain reaction; retrospective study; virus replication; fibrosis; lung adenocarcinoma; lung tumor
Financiación
Proyectos asociados
EFECTO DEL EXTRACTO DE Trametes versicolor SOBRE EL FENOTIPO Y LA FUNCIÓN DE CÉLULAS DENDRÍTICAS HUMANAS CONDICIONADAS CON MEDIOS DE CÉLULAS DE CARCINOMA ORAL
Investigador Principal: ANDRES FELIPE CARDONA MENDOZA
PCI-2019-10805 . 2020
Citar la publicación
Rojas L,Mayorga D,Ruiz A,Rodríguez J,Cardona AF,Archila P,Avila J,Bravo M,Ricaurte L,Sotelo C,Arrieta O,Zatarain ZL,Carranza H,Otero J,Vargas C,Barrón F,Corrales L,Martín C,Recondo G,Pino LE,Bermudez MA,Gamez T,Ordoñez C,García JE,de Lima VC,Freitas H,Santoyo N,Malapelle U,Russo A,Rolfo C,Rosell R. Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors. ESMO Open. 2022. 7. (4):100500. IF:7,300. (1).